On May 29, 2025, HC Wainwright & Co. confirmed its ongoing support for Intellia Therapeutics (NTLA, Financial) by reiterating their 'Buy' rating for the company. The analyst responsible for this decision, Mitchell Kapoor, cited this endorsement reinforcing confidence in the company's prospects.
The price target for Intellia Therapeutics (NTLA, Financial) remains stable at $30.00 USD, consistent with previous projections. This consistent valuation highlights sustained expectations for the company's financial performance and potential growth.
The unaltered rating and price target suggest a stable outlook for Intellia Therapeutics (NTLA, Financial), as the company's strategic directions continue to align with analysts' predictions. Investors and stakeholders will likely monitor NTLA's development closely in the coming quarters.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 24 analysts, the average target price for Intellia Therapeutics Inc (NTLA, Financial) is $39.63 with a high estimate of $106.00 and a low estimate of $8.00. The average target implies an upside of 310.20% from the current price of $9.66. More detailed estimate data can be found on the Intellia Therapeutics Inc (NTLA) Forecast page.
Based on the consensus recommendation from 28 brokerage firms, Intellia Therapeutics Inc's (NTLA, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Intellia Therapeutics Inc (NTLA, Financial) in one year is $27.69, suggesting a upside of 186.65% from the current price of $9.66. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Intellia Therapeutics Inc (NTLA) Summary page.
